Prognostic significance of albumin-to-alkaline phosphatase ratio for overall survival in metastatic lung adenocarcinoma patients

Authors : Figen Öztürk Ergür, Ayperi Öztürk, Melahat Uzel Şener, Hasret Gizem Kurt, Özlem Özdağ

Pages : 1255-1260

Doi:10.32322/jhsm.1334103

View : 54 | Download : 106

Publication Date : 2023-10-29

Article Type : Research Paper

Abstract :Aims: This study aims to determine the prognostic significance of the pretreatment albumin/alkaline phosphatase ratio (AAPR) for overall survival in patients diagnosed with metastatic lung adenocarcinoma (MLA). Methods: The medical records of 459 patients diagnosed with MLA between 2010 and 2021 were retrospectively reviewed. The AAPR was calculated using blood test results obtained at the time of diagnosis. Results: The study identified the optimal threshold value for AAPR as 0.314. Patients with a high AAPR (AAPR>0.314) demonstrated significantly longer median survival and overall survival time compared to those with a low AAPR (AAPR ≤ 0.314) (p<0.001). Specifically, the median survival time for the low AAPR group was 2.13±0.29 (95% CI: 1.56-2.70) months, while the high AAPR group had a median survival time of 4.1±0.59 (95% CI: 2.90-5.23) months (p<0.001). The 1-year survival rates were 27.3% and 5.3% for the high and low AAPR groups, respectively (p<0.001). Additionally, an AAPR ≤ 0.314 increased the risk of death by 1.96 times at 1 year. Conclusion: The AAPR was significantly reduced in MLA patients, making it a significant biomarker for forecasting prognosis and directing treatment options for these patients.
Keywords : Metastatic Lung Adenocarcinoma, Albumin to Alkaline Phosphatase Ratio, prognostic factor, survival